Renal Research Institute Fellow Receives International Society of Nephrology Award

Share this page

Dr. Viviane Calice-Silva awarded for poster submission focused on cardiovascular disease in renal patients

NEW YORK CITY — Renal Research Institute (RRI), a division of Fresenius Medical Care North America, announced today that judges at the International Society of Nephrology’s (ISN) World Congress of Nephrology (WCN) in Cape Town, South Africa, have awarded RRI Research Fellow Dr. Viviane Calice-Silva the ISN’s Fellowship Poster 3rd prize.

Dr. Calice-Silva’s submission is entitled Multinational study of the relationship between fluid status and left ventricular structure and function in chronic hemodialysis patients. It presents the relationship between indicators of cardiac structure and function, determined by renal patients‘echocardiography and its relationship with fluid status assessed by the Body Composition Monitor (BCM), Fresenius Medical Care Germany.  Renal patients who were included in this study are from 11 countries.  While some of Dr. Calice-Silva’s results concur with observations in the general population, they have never previously been shown for a multinational population of hemodialysis patients.

“The ISN Fellowship prize was a great surprise and a very nice recognition,” said Dr. Calice-Silva.  “My fellowship at RRI has been of great inspiration, allowing me to meet people from different fields and regions of the world who work together with one unique aim, to improve patient care and outcomes. It has been a period of personal and professional learning that certainly will enable me to provide even better care for my patients in the future.”

Dr. Calice-Silva, a nephrologist who practices in Brazil, joined RRI as a Research Fellow in June 2014.  Nephrologists from approximately 30 countries have served as RRI fellows since the organization’s fellowship program was created in 1997.

“She’s doing outstanding work with us,” said Dr. Peter Kotanko, research director at RRI. “The award is really important. It is a great testament to how RRI interacts with academic institutions abroad.  These kinds of collaborations with academic institutions give rise to such really great research, which is internationally recognized.”

Dr. Calice-Silva’s primary work at RRI involves analyzing congestive heart failure, arrhythmia and sudden cardiac death data from the international Monitoring Dialysis Outcomes (MONDO) data base, to identify predictors of death due to these conditions. Her work at RRI will continue through the end of April 2015.

About Renal Research Institute
The Renal Research Institute (RRI), a division of Fresenius Medical Care North America, conducts research in collaboration with our academic and teaching hospital partners in the US and abroad, aimed at improving the health outcomes and quality of life of patients with renal disease. RRI operates dialysis clinics in six states, primarily under the Avantus Renal Therapy brand. Patients treated at an Avantus Renal Therapy clinic benefit most directly and immediately from the latest insights gained at RRI into improving renal care.  RRI puts its research findings and innovative technologies to work for our patients while setting a higher standard for quality of care.

About Fresenius Medical Care North America
Fresenius Medical Care North America (FMCNA) is the premier health care company focused on delivering the highest quality care to people with renal and other chronic conditions. Through its industry-leading network of dialysis facilities, outpatient cardiac and vascular labs and urgent care centers, as well as the country’s largest practice of hospitalist and post-acute providers, FMCNA provides coordinated health care services at pivotal care points for hundreds of thousands of chronically ill customers throughout the continent. As the world’s only vertically integrated renal company, it offers specialty pharmacy and laboratory services, and manufactures and distributes the most comprehensive line of dialysis equipment, disposable products and renal pharmaceuticals. (

Media Contact:
Jon Stone
Office: 781-699-9704
Cell: 781-392-4680